A carregar...
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit opioids. Buprenorphine, a µ-opioid receptor partial agonist and kappa opioid receptor antagonist, is now being developed as a monthly, sustained-release formulation (RBP-6000). The objective of this st...
Na minha lista:
| Publicado no: | J Clin Psychopharmacol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5549150/ https://ncbi.nlm.nih.gov/pubmed/26650971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000000434 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|